Hepatology

An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.

Results highlight increased safety and efficacy of curative HCV therapy among reproductive-age female patients compared with males, potentially preventing vertical infection transmission.

The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics including treatment eligibility, diagnostics, and service delivery.

Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.

Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.

SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.

Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.

New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.

The first-in-human trial of VRON-0200, a novel immunotherapy for chronic hepatitis B virus, presented at the APSAL meeting, demonstrates a promising safety and tolerability profile.

Patients with cirrhosis had greater health care costs than matched controls, attributed mostly to cirrhosis complications and high inpatient utilization in the first year after diagnosis.

The phase 2, proof-of-concept LEGEND trial achieved its primary efficacy endpoint for absolute reduction in HbA1c at week 24 with lanifibranor alone or in combination with empagliflozin.

A recent survey found telemedicine-based HCV treatment at a syringe access program could improve access to treatment among people who inject drugs.

In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.

Test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV guideline!

In a landmark decision, the FDA has granted accelerated approval to resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis.

Saeed Mohammed, MD, MS, discusses maralixibat for pruritus in PFIC, describing how IBAT inhibitors have changed the way clinicians are able to treat cholestatic liver disease.

Treatment with DAA therapy at 3 years of age was associated with better health outcomes and cost savings versus deferring initiation to 6 years of age or older.

The phase 3 ENLIGHTEN program will consist of 2 phase 3 trials evaluating the safety and efficacy of pegozafermin in patients with MASH.

Curative DAA therapy did not completely normalize immune activation and inflammatory biomarkers in individuals with a history of injection drug use and HCV infection.

Although abstinence is the safest approach, patients with SLD at low risk for advanced fibrosis can safely consume < 7.4 g/day of alcohol, equivalent to half of a standard US drinking unit.

Seropositivity was associated with greater albuminuria but not peripheral artery disease in a cohort of patients ≥ 50 years of age with type 2 diabetes mellitus.

Our February 2024 month in review highlights some of our top hepatology content from the past few weeks, including pipeline updates, phase 2/3 trial data, and new research in liver diseases.

Results showed 95.8% of patients who were treated for HCV with DAA therapy and underwent renal transplantation did not experience HCV recurrence.

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.

Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.

Cross-sectional survey results suggest most providers are recommending HCV screening based on patient risk factors rather than universally for all patients 18-79 years of age.

Survodutide, a dual agonist from Boehringer Ingelheim and Zealand Pharma, was associated with MASH resolution without worsening fibrosis among 83% of participants in a phase 2 trial.

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.